Health Trials

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

ConditionsStrokeChronic StrokeIntracerebral HaemorrhageIntracerebral Haemorrhage (ICH)Intracerebral Hemorrhage Basal GangliaIschemic StrokeIschemic Stroke and Hemorrhagic StrokeHemiparesis After StrokeHemiplegia Following Ischemic StrokeHemiplegia and HemiparesisHemiplegia and/or Hemiparesis Following StrokeMiddle Cerebral Artery Stroke
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorJohns Hopkins University

About this trial

The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.

Eligibility criteria

Qualifiers

Over age 18 years, inclusive.

Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date

Ability to give informed consent and understand the tasks involved.

Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team

Disqualifiers

selective serotonin reuptake inhibitor (SSRI)

Serotonin-norepinephrine reuptake inhibitors (SNRI)

Buproprion

Valproic acid

Trial design

Treatments tested in this trial

  • Psilocybin (Usona Institute)

Treatment groups

20 Participants
are divided into 2 treatment groups

Locations

1
Johns Hopkins21287, BaltimoreMaryland, United States

Sponsors and collaborators

Johns Hopkins University

Lead sponsor

Rose Hill

Collaborator

Usona Institute

Collaborator

University of California, Berkeley

Collaborator

Source ClinicalTrials.gov